Wyeth is now a wholly owned subsidiary of Pfizer — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Wyeth is now a wholly owned subsidiary of Pfizer appears in 176 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials176

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-AdministeredNCT00966966 · lead sponsor · 2009-09-01

Study Evaluating The Coadministration of Begacestat And DonepezilNCT00959881 · lead sponsor · 2009-08-01

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective DisorderNCT00892021 · lead sponsor · 2009-05-01

Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male SubjectsNCT00906191 · lead sponsor · 2009-05-01

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive DisorderNCT00863798 · lead sponsor · 2009-04-01

Study Evaluating Effexor XR in Chinese Subjects With Major Depressive DisorderNCT00878748 · lead sponsor · 2009-04-01

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive DisorderNCT00824291 · lead sponsor · 2009-02-01

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic PatientsNCT00781794 · lead sponsor · 2009-01-01

Study Evaluating HTC-867 in Healthy Young and Elderly SubjectsNCT00827489 · lead sponsor · 2009-01-01

Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789NCT00795730 · lead sponsor · 2009-01-01

Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese SubjectsNCT01268124 · lead sponsor · 2008-12-01

Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in AustraliaNCT00751387 · lead sponsor · 2008-11-01

A Multicenter Study to Compare the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Treatment of Rheumatoid ArthritisNCT00783536 · lead sponsor · 2008-11-01

Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of SchizophreniaNCT00768612 · lead sponsor · 2008-11-01

Evaluation of EULAR-RAID Score in Rheumatoid Arthritis PatientsNCT00768053 · lead sponsor · 2008-10-01

Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy SubjectsNCT00759837 · lead sponsor · 2008-10-01

Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-AdministeredNCT00745576 · lead sponsor · 2008-10-01

Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild AsthmaNCT00725582 · lead sponsor · 2008-09-01

Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA SubjectsNCT00706797 · lead sponsor · 2008-09-01

Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531NCT00726115 · lead sponsor · 2008-08-01

Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's DiseaseNCT00739037 · lead sponsor · 2008-08-01

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive DisorderNCT00669110 · lead sponsor · 2008-05-01

Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsNCT00684710 · lead sponsor · 2008-04-01

Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy SubjectsNCT00777530 · lead sponsor · 2008-04-01

Study Evaluating Safety of GSI 136 in Young and Elderly Japanese MalesNCT00719394 · lead sponsor · 2008-03-01

Study GSI-136 in Healthy Young and Healthy Elderly SubjectsNCT00718731 · lead sponsor · 2008-03-01

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive DisorderNCT00619619 · lead sponsor · 2008-02-01

Study Evaluating Multiple Ascending Dose in Schizophrenia PatientsNCT00620568 · lead sponsor · 2008-02-01

Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia PatientsNCT00581243 · lead sponsor · 2008-01-01

Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and DigoxinNCT00563732 · lead sponsor · 2007-12-01

Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy SubjectsNCT00519298 · lead sponsor · 2007-10-01

Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor OccupancyNCT00499200 · lead sponsor · 2007-10-01

Study Evaluating Multiple Doses Of GSI-953 Within The Elderly PopulationNCT00547560 · lead sponsor · 2007-08-01

Study Comparing Bioavailability of Oral Formulations of VabicaserinNCT00541996 · lead sponsor · 2007-08-01

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male SubjectsNCT00505973 · lead sponsor · 2007-07-01

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDDNCT00445679 · lead sponsor · 2007-07-01

Study Comparing Lecozotan SR Two 5-mg Tablets Vs. Lecozotan SR One 10-mg Tablet in Healthy SubjectsNCT00494962 · lead sponsor · 2007-06-01

Study Evaluating the Effect of Lecozotan SR on the QTc IntervalNCT00499642 · lead sponsor · 2007-06-01

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315NCT00474552 · lead sponsor · 2007-06-01

Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific RegionNCT00422227 · lead sponsor · 2007-06-01

Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's DiseaseNCT00481520 · lead sponsor · 2007-06-01

Study Evaluating GSI-953 in Healthy Young and Alzheimer's PatientsNCT00479219 · lead sponsor · 2007-05-01

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531NCT00479349 · lead sponsor · 2007-05-01

A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid ArthritisNCT00484237 · lead sponsor · 2007-04-01

Study Evaluating Health Related Utility in Rheumatoid ArthritisNCT00471874 · lead sponsor · 2007-04-01

Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female SubjectsNCT00458107 · lead sponsor · 2007-04-01

Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed PatientsNCT00474708 · lead sponsor · 2007-04-01

Single Ascending Dose Study of SRA-444 in Healthy SubjectsNCT00452504 · lead sponsor · 2007-02-01

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)NCT00440427 · lead sponsor · 2007-02-01

Open Label, Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RANCT00418717 · lead sponsor · 2007-02-01

Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953NCT00441987 · lead sponsor · 2007-02-01

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.NCT00366249 · lead sponsor · 2007-01-01

Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the HeartNCT00447629 · lead sponsor · 2007-01-01

Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 PathwayNCT00456898 · lead sponsor · 2007-01-01

Study Evaluating PPM-204 In Subjects With Type 2 DiabetesNCT00425919 · lead sponsor · 2007-01-01

Study Evaluating Bifeprunox in Patients With Schizophrenia.NCT00366327 · lead sponsor · 2007-01-01

Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid ArthritisNCT00440492 · lead sponsor · 2006-12-01

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal WomenNCT00406640 · lead sponsor · 2006-12-01

Study Evaluating the Clinical and Therapeutic Management of Rheumatoid Arthritis in SpainNCT00881881 · lead sponsor · 2006-12-01

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary EndpointNCT00366704 · lead sponsor · 2006-11-01

Drugs studied in this sponsor's trials

37 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Wyeth is now a wholly owned subsidiary of Pfizer as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo14

etanercept13

methotrexate4

temsirolimus4

donepezil3

paroxetine3

sirolimus3

desipramine2

placebo RxCUI 8375 · Lead sponsor in 12 linked trial(s) · 0 currently recruiting 14 trials etanercept RxCUI 214555 · Lead sponsor in 11 linked trial(s) · 0 currently recruiting 13 trials methotrexate RxCUI 6851 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 4 trials temsirolimus RxCUI 657797 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials donepezil RxCUI 135447 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials paroxetine RxCUI 32937 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials sirolimus RxCUI 35302 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials desipramine RxCUI 3247 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials mitoxantrone RxCUI 7005 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials quetiapine RxCUI 51272 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials ramipril RxCUI 35296 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials risperidone RxCUI 35636 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials zidovudine RxCUI 11413 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials aripiprazole RxCUI 89013 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial bosutinib RxCUI 1307619 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial codeine RxCUI 2670 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial desvenlafaxine 100 MG RxCUI 790262 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial desvenlafaxine 50 MG RxCUI 790287 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial desvenlafaxine succinate RxCUI 683693 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial duloxetine RxCUI 72625 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Effexor RxCUI 151692 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial Enbrel RxCUI 216891 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial erlotinib RxCUI 337525 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor133

collaborator43

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.